Bavarian Nordic

Avitide discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products. Avitide has successfully deployed affinity purification technologies towards an array of biological molecules including enzymes, bispecific antibodies, therapeutic scaffolds, growth factors, hormones, insulins, blood factors, Fcfusions, cell-based therapies, vaccines, and gene therapy viral vectors. Avitide's management team brings substantial industry expertise and a successful track record in commercializing innovative biopharmaceutical manufacturing platforms. Avitide is financed by premier venture capital and private equity firms, including Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, Sands
Capital Ventures, Section 32, SV Health Investors, Borealis Ventures, and NeoMed Management. For more information, visit www.avitide.com.

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins.

With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids.

CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, viral vaccines and exosomes.

With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

Gyros Protein Technologies provides enabling peptide synthesis and immunoassay bioanalytical tools that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.

With a large and growing installed base of instruments for nanoliter scale immunoassay automation (Gyrolab® xPand, Gyrolab xP workstation and Gyrolab xPlore™), and peptide synthesis (PurePep™ Chorus, Symphony® X and Sonata® XT) in the biopharmaceutical industry and related markets, the solutions from Gyros Protein Technologies accelerate discovery, development, and manufacturing of safer and more efficacious biotherapeutics, cell & gene therapies and vaccines. Gyros Protein Technologies is a division of Mesa Laboratories.

IDT Biologika is a contract development and manufacturing organization with almost 100 years of experience in development and manufacture of live viral vaccines, gene and immune therapeutics, and fill/finish of biologics for the global protection of human health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply.

Recognized for its technically sophisticated contract development, manufacture and handling of biopharmaceuticals in EMA- and FDA-inspected facilities, IDT Biologika has developed into one of the world's leading pharmaceutical and biotechnological companies.
The company's headquarters are located in Dessau-Rosslau , Germany. In the United States, IDT Biologika Corp. is responsible for sales activities throughout North America.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.